Entera Current Deferred Revenue from 2010 to 2024

ENTX Stock  USD 1.64  0.06  3.53%   
Entera Bio Current Deferred Revenue yearly trend continues to be fairly stable with very little volatility. Current Deferred Revenue will likely drop to about 36.8 K in 2024. Current Deferred Revenue is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. View All Fundamentals
 
Current Deferred Revenue  
First Reported
2010-12-31
Previous Quarter
38.7 K
Current Value
36.8 K
Quarterly Volatility
337.1 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Entera Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Entera Bio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 97.3 K, Interest Expense of 31.4 M or Selling General Administrative of 5.2 M, as well as many indicators such as Price To Sales Ratio of 79.86, Dividend Yield of 0.0 or PTB Ratio of 1.76. Entera financial statements analysis is a perfect complement when working with Entera Bio Valuation or Volatility modules.
  
Check out the analysis of Entera Bio Correlation against competitors.
For more information on how to buy Entera Stock please use our How to Invest in Entera Bio guide.

Latest Entera Bio's Current Deferred Revenue Growth Pattern

Below is the plot of the Current Deferred Revenue of Entera Bio over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Entera Bio's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Entera Bio's overall financial position and show how it may be relating to other accounts over time.
Current Deferred Revenue10 Years Trend
Very volatile
   Current Deferred Revenue   
       Timeline  

Entera Current Deferred Revenue Regression Statistics

Arithmetic Mean257,164
Geometric Mean151,700
Coefficient Of Variation131.06
Mean Deviation157,956
Median225,000
Standard Deviation337,052
Sample Variance113.6B
Range1.4M
R-Value(0.02)
Mean Square Error122.3B
R-Squared0.0005
Significance0.94
Slope(1,716)
Total Sum of Squares1.6T

Entera Current Deferred Revenue History

202436.8 K
202338.7 K
202243 K
202115 K
20201.4 M
2019267 K

About Entera Bio Financial Statements

Entera Bio investors use historical fundamental indicators, such as Entera Bio's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Entera Bio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue38.7 K36.8 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Entera Stock Analysis

When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.